Abstracts Archive - Page 332 of 1683 - ATC Abstracts

2020 American Transplant Congress
Taking on Pediatric Liver Tumors – Beyond Hepatoblastoma
U. Ekong, N. Yazigi, K. Khan, S. Kaufman, J. Guerra, R. Girlanda, J. Hawksworth, A. Kroemer, C. Matsumoto, T. Fishbein
MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: Background. Hepatic angiosarcomas, hepatocellular carcinoma, hemangioendothelioma, and rhabdomyosarcoma of the bile ducts are very rare tumors in children with historically poor prognosis. Median survival…
2020 American Transplant Congress
Is the Survival Impacted by Multiple Cancer after Liver Transplantation? A Retrospective French National Multicentric Study between 1993-2013
M. Altieri
Chu Caen, Caen, France
*Purpose: Introduction: Despite the great progress made in recent decades, post-liver transplant de novo cancers is one of the leading causes of late complications and…
2020 American Transplant Congress
From Marginal to Meaningful: Donor Liver Biopsy Increases Donation Rates amongst Elderly Donors
J. A. Steggerda¹, M. B. Bloom¹, K. Mahendraraj¹, G. Voidonikolas¹, T. Todo¹, M. Noureddin², N. N. Nissen¹, A. S. Klein¹, I. K. Kim¹
¹Surgery, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA, ²Hepatology, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA
*Purpose: Recently, there has been public scrutiny on the non-utilization of elderly donors in liver transplantation. Here, we evaluate the influence of donor liver biopsy…
2020 American Transplant Congress
Uncontrolled DCD vs DBD Liver Transplantation in the United States: Is it Safe to Push the Envelope?
R. A. Choudhury¹, D. Yoeli¹, H. Yaffe¹, H. B. Moore¹, G. Hoeltzel², A. Schulick¹, K. D. Conzen¹, J. J. Pomposelli¹, E. A. Pomfret¹, T. L. Nydam¹
¹Department of Surgery- Division of Transplantation Surgery, University of Colorado Hospital, Aurora, CO, ²Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: Uncontrolled donation after cardiac death (uDCD) liver transplantation has been theorized as a potential option to increase the donor pool due to the typical…
2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
M. L. Goldman¹, K. Zhou², J. L. Dodge¹, F. Yao¹, N. Mehta¹
¹Department of Medicine, UCSF, San Francisco, CA, ²Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but
2020 American Transplant Congress
Outcomes of Intra-Operative Steroid Induction in Liver Transplant Recipients
A. Poparad-Stezar, A. Jantz, T. Larson, B. Summers, N. Sulejmani
Henry Ford Hospital, Detroit, MI
*Purpose: Evidence supporting the use of antibody induction (AI) immunosuppression (IS) (antithymocyteglobulin (rATG) and basiliximab (BAS)) for acute rejection (AR) prophylaxis in liver transplant is…
2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
P. Tabrizian¹, M. Holzner², V. Agopian³, R. Busuttil³, G. Sapisochin⁴, N. Mehta⁵, F. Yao⁵, J. Roberts⁶, S. Florman¹, M. E. Schwartz¹, T. Ivanics⁷, J. Emond⁸, B. Samstein⁹, R. Brown, MD, MPH⁹, M. Najjar¹⁰, W. Chapman¹¹, M. Doyle¹¹, K. Halazun⁹
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Surgery, Georgetown University Hospital, Washington DC, MD, ³Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Transplant, Univeristy of Toronto, Toronto, ON, Canada, ⁵Transplant, UCSF, San Francisco, CA, ⁶Transplantation, UCSF, San Francisco, CA, ⁷Transplant, University of Toronto, Toronto, ON, Canada, ⁸Transplant, Columbia University Medical Center, New York, NY, ⁹Transplant, Weill Cornell Medical Center, New York, NY, ¹⁰Transplant, Columbia Medical Center, New York, NY, ¹¹Transplant, Washington University School of Medicine, St Louis, MO
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…
2020 American Transplant Congress
The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma
K. Sasaki¹, J. McVey¹, D. Firl², Y. Inaba³, C. D. Kwon¹, K. Hashimoto¹, F. Aucejo¹
¹The Cleveland Clinic, Cleveland, OH, ²Duke University, Durham, NC, ³Chiba University, Chiba, Japan
*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…
2020 American Transplant Congress
Patients in Donor Service Areas with Higher Median MELD at Transplant Have a Lower Probability of Liver Transplant Waitlist Activation
J. Merola¹, S. Noreen², D. Stewart², R. Batra¹, D. Haakinson¹, G. Gan³, Y. Deng³, S. Kulkarni¹
¹Yale School of Medicine, New Haven, CT, ²United Network of Organ Sharing, Richmond, VA, ³Yale Center for Analytical Sciences, Yale University, New Haven, CT
*Purpose: US allocation of hepatic allografts is prioritized based on medical need, however significant geographical disparities exist with median MELD at transplant across donor specific…
2020 American Transplant Congress
Shorter Waiting Time Was Associated with Higher Risk of Recurrence of Hepatocellular Carcinoma in Liver Transplantation
T. Kitajima¹, S. Nagai¹, D. Moonka², S. Yeddula¹, O. Rizzo¹, M. Kavousi¹, R. Salgia², M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Liver transplantation (LT) is an established treatment option for hepatocellular carcinoma (HCC). After 6-month waiting rule was implemented, the impact of wait-listing (WL) time…